Page 228 - 2021_06-Haematologica-web

Letters to the Editor
Genentech, Janssen, MEI Pharma, Pharmacyclics, Research to Practice, Syros Pharmaceuticals, TG Therapeutics, Verastem, and Zentalis, and has received institutional research funding from Ascentage, AstraZeneca, Genentech, MEI Pharma, Pharmacyclics, Surface Oncology, TG Therapeutics, and Verastem. The other authors have no conflicts of interest to disclose.
Contributions: CK, CH, BB, CG, PC, SJFC, LK and EK performed research; SP, OT, RJ, MEM and ISK provided material and performed expanded diagnostics on patients’ samples; GH, WRS, DH, MR, UJ and PBS managed and treated patients; CK, CH, TP, SK, MSD and PBS analyzed the data; CK, TP, PBS wrote the manuscript; MSD and PBS supervised the study.
Acknowledgments: our screening compound libraries are from the NIH clinical collection, gifts from F. Bracher, T. Nielsen, S. Nijman, J. Bradner, The Broad Institute, and Haplogen GmbH.
Funding: we acknowledge funding from the Austrian Science Fund (FWF) TRANSCAN-2 grant ERANET-PLL I 4156B, FWF TRANSCAN-2 grant EuroTCLym I 4154B, FWF grant P27132-B20 (to PBS), Vienna Science and Technology Fund (WWTF) grant LS16-034 (to UJ)and the Anniversary Fund of the Oesterreichische Nationalbank (OeNB) grant P15936 (to PBS).
We further acknowledge funding from the Canadian Institutes of Health Research (CIHR; FRN-152986 and FRN-408093 (to CG), and the Canada Research Chair Program. CG holds a Canada Research Chair in pharmacogenomics (Tier 1).
References
1. Staber PB, Herling M, Bellido M, et al. Consensus criteria for diagno- sis, staging, and treatment response assessment of T-cell prolympho- cytic leukemia. Blood. 2019;134(14):1132-1143.
2. Stengel A, Kern W, Zenger M, et al. Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prog- nostic marker. Genes Chromosomes Cancer. 2016;55(1):82-94.
3. Wiktor-Jedrzejczak W, Drozd-Sokolowska J, Eikema DJ, et al. EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL). Bone Marrow Transplant. 2019;54(9):1391-1398.
4.Boidol B, Kornauth C, Kouwe E van der, et al. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood. 2017;130(23):2499-2503.
5. Andersson EI, Pützer S, Yadav B, et al. Discovery of novel drug sen- sitivities in T-PLL by high-throughput ex vivo drug testing and muta- tion profiling. Leukemia. 2018;32(3):774-787.
6. Dietrich S, Oleś M, Lu J, et al. Drug-perturbation-based stratification of blood cancer. J Clin Invest. 2018;128(1):427-445.
7. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irre- versible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539-2549.
8.Dondorf S, Schrader A, Herling M. Interleukin-2-inducible T-cell kinase (ITK) targeting by BMS-509744 does not affect cell viability in T-cell prolymphocytic leukemia (T-PLL). J Biol Chem. 2015; 290(16):10568-10569.
9. Koch R, Christie AL, Crombie JL, et al. Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood. 2019;133(6):566-575.
10. Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018; 378(13):1211-1223.
11. Jain N, Keating M, Thompson P, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380(22):2095-2103.
12. Liu Y, Wang X, Deng L, et al. ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma. Cancer Cell Int. 2019; 19(1):32.
13. Smith VM, Lomas O, Constantine D, et al. Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia. Blood Adv. 2020; 4(3):525-529.
14. Oberbeck S, Schrader A, Warner K, et al. Noncanonical effector func- tions of the T-memory–like T-PLL cell are shaped by cooperative TCL1A and TCR signaling. Blood. 2020;136(24):2786-2802.
15. Alfayez M, Thakral B, Jain P, et al. First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). Leuk Lymphoma. 2020;61(2):445-449.
2256
haematologica | 2021; 106(8)